Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose **combination drug** of **thiamine**, **pyridoxine**, **cyanocobalamin**, **diclofenac**, and **tizanidine**. - **Diclofenac** is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes, blocking prostaglandin synthesis, thus reducing pain and inflammation[1][4][5]. - **Tizanidine** is a centrally acting skeletal muscle relaxant that is an agonist at α2-adrenergic receptors, reducing muscle tone by inhibiting spinal polysynaptic reflexes[1][4][5]. - **Thiamine (vitamin B1)**, **pyridoxine (vitamin B6)**, and **cyanocobalamin (vitamin B12)** are B group vitamins often included for their roles in nerve health and metabolism but have no direct analgesic or muscle relaxant effect; their addition is generally to support nerve health during the management of musculoskeletal pain and neuropathy. The primary indication for this combination is the **symptomatic treatment of musculoskeletal pain with associated muscle spasms**—such as acute low back pain, neck pain, joint pain, and spasticity. It also provides supportive micronutrients that may assist in nerve regeneration or recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine + pyridoxine + cyanocobalamin + diclofenac + tizanidine.